

Substitute for form 1449A/PTO		<i>Complete If Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	Unassigned
		Filing Date	Herewith
		First Named Inventor	Puri, Srinivasulu
		Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	1	of	2
		Attorney Docket Number	021756-005300US

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	/David Garcia Cervetti/	Date Considered	02/12/2007
--------------------	-------------------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60096472 v1

Substitute for form 1449B/PTO				Complaint Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	Unassigned
				<i>Filing Date</i>	Herewith
				<i>First Named Inventor</i>	Puri, Srinivasulu
				<i>Art Unit</i>	Unassigned
				<i>Examiner Name</i>	Unassigned
Sheet	2	of	2	Attorney Docket Number	
021756-005300US					

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
DGC	AI	"FDA 21 CFR Part 11," Document Resources, http://www.documentresources.com/documents/21cfrpart11.html , pp. 1-2, printed June 23, 2003.			
DGC	AJ	'The Role of Technology Solutions in the Pharmaceutical and Biotechnology Industries' Search for 21 CFR Part 11 Compliance," Life Science CIO Forum, www.lifesciencesCIOforum.com , pp. 1-7 (2002).			
DGC	AK	'21CFR Part 11 Opportunity or Challenge? With an Analysis of Oracle's OPM," Life Science CIO Forum, www.lifesciencesCIOforum.com , pp. 1-14 (2002).			

Examiner Signature	/David Garcia Cervetti/	Date Considered	02/12/2007
--------------------	-------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.